Tag Archives: Biotech

California Life Sciences to Partner with China

BIOCOM, a trade group representing Southern California’s life sciences industry, is ramping up partnership efforts in China to meet an emerging desire for novel drug therapies. While intellectual property (IP) protections and the Chinese government’s willingness to pay for expensive new products represent two large and lingering question marks, Joe Panetta, president and CEO at […]
Posted in Biotech, Emerging Markets, Global, IP, leadership, Market Access, R&D | Also tagged , , , | Leave a comment

Gilead Buys CV Therapeutics (Update 1)

The morning’s other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that it will purchase CV Therapeutics for $1.4 billion. The sudden move frees Palo Alto-based cardiovascular company CV Therapeutics from the hostile embrace of Astellas Pharma, ending a messy $1.1 billion takeover attempt. With the acquisition, Gilead, […]
Posted in Deals | Also tagged , , , , , , | 3 Comments

Gilead Making a Bundle

Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech […]
Posted in Biotech, Emerging Markets, R&D | Also tagged , , | Leave a comment

Simply Genius: Prix Galien USA 2008 (photos)

Click here to view a slideshow from Prix Galien 2008 The 2008 Prix Galien USA is in the books, and Pharm Exec was in attendance at New York’s Museum of Natural History to take in all the festivities. Pfizer, Merck, Alexion, Wyeth, and Celgene were all recognized for their work in advancing science in both […]
Posted in Biotech, Events, People | Also tagged , , , , , , , | Leave a comment

The Real China Strategy

There’s a lot of talk these days about India and China as potential markets and as sources for cheap manufacturing and R&D. But the real potential of these countries is far more interesting: As China and India (and Brazil, Russia, and Korea) learn to create new products, they’re going to do it at price points […]
Posted in Biotech, Deals, Emerging Markets, Strategy | Also tagged , , , , | 10 Comments
  • Categories

  • Meta